Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug ...

Zorevunersen is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both ...

Besides zorevunersen, STOK is also looking to develop another candidate, STK-002, for the treatment of autosomal dominant optic atrophy. STOK's Zacks Rank & Rising Estimates.

Zorevunersen is being developed as potentially. BEDFORD, Mass., December 04, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by ...

Zorevunersen is a Potential First-in-Class Disease Modifying Medicine for Dravet Syndrome. Zorevunersen has been granted FDA Breakthrough Therapy Designation based on preliminary clinical evidence ...

Zorevunersen is an investigational antisense oligonucleotide that works by upregulating the NaV1.1 protein. The FDA has granted Breakthrough Therapy designation to zorevunersen for the treatment ...

Called zorevunersen, the Stoke drug has shown potential to become the first treatment to target the underlying, genetic cause of the condition. Skip to Main Content. Manage alerts for this article; ...

Stoke Therapeutics (STOK) announced new data from an analysis of nine patients treated with an initial 2 or 3 doses of 70mg, followed by 45mg maintenance dosing in the Phase 1/2a and open-label ...

LOS ANGELES — Zorevunersen led to 75% to 80% seizure reduction in patients with Dravet syndrome, according to Barry S. Ticho, MD, PhD, FACC, chief medical officer of Stoke Therapeutics.&ldquo ...

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Stoke Therapeutics (STOK – Research Report) and keeping the price target at $35.00. Andrew Fein has given his Buy rating due ...

Zorevunersen is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, ...